ROCKVILLE, Md.--(BUSINESS WIRE)--Celek Pharmaceuticals today announced that the National Cancer Institute (NCI) has awarded the Company a Phase I Small Business Innovation Research (SBIR) Contract to support development of CEL-031, Celek’s targeted, first-in-class oncology drug candidate for the treatment of bladder cancer. Celek was selected for this $176,266 award based on a competitive review following NCI’s request for proposals on the development of novel anticancer agents.
